Q-omics provides the consensus-scored MBLAC2 profile across patient tissues and cancer cell-line models. MBLAC2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MBLAC2 is differentially expressed in 9, with the highest sampling consensus in UCEC. Additionally, MBLAC2 protein abundance shows 23,946 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, UCEC, and GBM as cancer lineages where MBLAC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBLAC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBLAC2 survival associations across molecular data types. MBLAC2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBLAC2 RNA expression–survival associations across cancer types. High MBLAC2 expression shows unfavorable associations in UVM and OV, but favorable associations in KIRC, HNSC, ACC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MBLAC2 RNA expression.
This table summarizes MBLAC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MBLAC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBLAC2 shows lower tumor expression in UCEC, THCA and BRCA and higher tumor expression in COAD, READ and KIRC. The UCEC box plot shows higher MBLAC2 RNA expression in normal versus tumor tissue (log2 FC = −1.204, t-test p < 0.001).
This table shows molecular features associated with MBLAC2 in patient tissues and cancer cell lines. In patient samples, MBLAC2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MBLAC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
